

# Giulia Rovesti

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/3718029/giulia-rovesti-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

21  
papers

238  
citations

8  
h-index

15  
g-index

23  
ext. papers

350  
ext. citations

4.7  
avg, IF

3  
L-index

#	Paper	IF	Citations
21	Soluble TRAIL Armed Human MSC As Gene Therapy For Pancreatic Cancer. <i>Scientific Reports</i> , <b>2019</b> , 9, 1788	4.9	36
20	Management of adverse events with tailored sorafenib dosing prolongs survival of hepatocellular carcinoma patients. <i>Journal of Hepatology</i> , <b>2019</b> , 71, 1175-1183	13.4	35
19	Inducible Caspase9-mediated suicide gene for MSC-based cancer gene therapy. <i>Cancer Gene Therapy</i> , <b>2019</b> , 26, 11-16	5.4	28
18	MSC-Delivered Soluble TRAIL and Paclitaxel as Novel Combinatory Treatment for Pancreatic Adenocarcinoma. <i>Theranostics</i> , <b>2019</b> , 9, 436-448	12.1	25
17	Impact of Baseline Characteristics on the Overall Survival of HCC Patients Treated with Sorafenib: Ten Years of Experience. <i>Gastrointestinal Tumors</i> , <b>2019</b> , 6, 92-107	1.3	19
16	H-NMR Based Serum Metabolomics Highlights Different Specific Biomarkers between Early and Advanced Hepatocellular Carcinoma Stages. <i>Cancers</i> , <b>2020</b> , 12,	6.6	19
15	and Polymorphisms and Clinical Outcome in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib. <i>Cancers</i> , <b>2019</b> , 11,	6.6	19
14	Association of and Gene Polymorphisms with Survival in Patients with Hepatocellular Carcinoma Receiving Sorafenib: Results of the Multicenter Prospective INNOVATE Study. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 4485-4493	12.9	9
13	Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma. <i>Targeted Oncology</i> , <b>2020</b> , 15, 773-785	5	8
12	First-line gemcitabine plus nab-paclitaxel for elderly patients with metastatic pancreatic cancer: Crossing the frontier of age?. <i>European Journal of Cancer</i> , <b>2020</b> , 137, 108-116	7.5	6
11	The Growing Skyline of Advanced Hepatocellular Carcinoma Treatment: A Review. <i>Pharmaceuticals</i> , <b>2021</b> , 14,	5.2	6
10	Prognostic role of a new index (multi inflammatory index) in patients with metastatic colorectal cancer: results from the randomized ITACa trial. <i>Therapeutic Advances in Medical Oncology</i> , <b>2020</b> , 12, 1758835920958363	5.4	5
9	BRCA in Gastrointestinal Cancers: Current Treatments and Future Perspectives. <i>Cancers</i> , <b>2020</b> , 12,	6.6	5
8	Impact of Aspirin on clinical outcome in advanced HCC patients receiving sorafenib and regorafenib. <i>Hpb</i> , <b>2021</b> , 23, 915-920	3.8	4
7	Prognostic Role of a New Index (RAPID Index) in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib: Training and Validation Cohort. <i>Gastrointestinal Tumors</i> , <b>2019</b> , 6, 71-80	1.3	4
6	Clinical Implications of Malnutrition in the Management of Patients with Pancreatic Cancer: Introducing the Concept of the Nutritional Oncology Board. <i>Nutrients</i> , <b>2021</b> , 13,	6.7	3
5	Retrospective survival analysis in patients with metastatic pancreatic ductal adenocarcinoma with insulin-treated type 2 diabetes mellitus. <i>Tumori</i> , <b>2021</b> , 107, 550-555	1.7	2

4	Liquid Biopsy in Hepatocellular Carcinoma: Opportunities and Challenges for Immunotherapy. <i>Cancers</i> , <b>2021</b> , 13,	6.6	2
3	TRAIL receptors are expressed in both malignant and stromal cells in pancreatic ductal adenocarcinoma. <i>American Journal of Cancer Research</i> , <b>2021</b> , 11, 4500-4514	4.4	
2	Validation and refinement of PROSASH model using the neutrophil-to-lymphocyte ratio in patients with HCC receiving sorafenib. <i>Liver Cancer International</i> , <b>2020</b> , 1, 6-11	0.8	
1	A Novel Prognostic Tool in Western and Eastern Biliary Tract Cancer Patients Treated in First-line Setting: the ECSIPOT Index. <i>Journal of Gastrointestinal Cancer</i> , <b>2021</b> , 1	1.6	